Member Info for Bebeto

They also still have to have funds to complete COPD trial.

Interesting extract from 18th March RNS: "We have also shown that treatment with inhaled SNG001 reduced lung viral load and lung pathology in an in vivo swine flu driven model of viral pneumonia."

A key difference between SARS-CoV & SARS-CoV2 (Covid-19) is the timeline of max viral load. Covid-19 is a lot sooner when symptoms start.

They filed this today: Second filing of a statement of capital following an allotment of shares on 28 February 2020

GBP 6,221,539.69

Saudi Aramco shares have recovered to level before the oil crash.

UOG investor taken note.

Not a great day for day traders on here today LOL

Options, warrants, block build's, investors should expect them all to be exercised it's not like GGP are generating much revenues at the moment.

Extract from 18th March 2020 RNS:

"At the time of the MERS-CoV outbreak in 2013, Synairgen collaborated with the National Institutes of Health (NIH) in the US to show that SNG001 could protect against MERS-CoV infection of lung cells in vitro."

This is very interesting, SNG001 protects against MERS-CoV (in the laboratory) because the genome between Covid-19 and MERS is 50% the same.

"At the whole-genome level, the SARS-CoV-2 shares an 87.99% sequence identity with the bat-SL-CoVZC45 and 87.23% sequence identity with the bat-SL-CoVZXC2, less genetically similar to the SARS-CoV (about 79%) and MERS-CoV (about 50%) "

The current shareprice is where the market puts it. There's an estimated 106,695,477 shares in the float and only 1,713,149 shares was traded today. The shareprice is still above the 21day upward trending moving average line. This is just the shareprice movement lull period before the buying in for news pressure to move up the shareprice to the next level.

WTI crude up 9.85% , Brent up 8.25%, Natural gas up 8.69%, UOG up 4.84%, things are looking up here.!

Extract from 18th March 2020 RNS:

"Two Phase II clinical trials in asthma showed that inhaled SNG001 treatment activated antiviral pathways in the lung along with improving lung function in patients with a respiratory viral infection. We have also shown that treatment with inhaled SNG001 reduced lung viral load and lung pathology in an in vivo swine flu driven model of viral pneumonia. At the time of the MERS-CoV outbreak in 2013, Synairgen collaborated with the National Institutes of Health (NIH) in the US to show that SNG001 could protect against MERS-CoV infection of lung cells in vitro."

Not frustrated I'm looking forward to seeing the results.

Agree, also progression & evolution to pneumonia is a secondary endpoint. The mortality rate from having pneumonia is also a consideration/ variable. Only the phase 2 data results can answer the variable questions but were the deaths found to be higher or the same as the similar close by hospital it would be less interesting.

True about 20% less deaths.

"the pilot phase of the study will involve 100 COVID-19 patients, will take place across a number of NHS trusts"

Lots of variables to play out, Southampton just being one hospital used. Interesting all the same.

That's interesting, less than 20 miles apart with Southampton having 10% more people and over 40 less Covid-19 fatalities. Hopefully it's connected to our trial and the start of something.

Hannam did us all a good favour with their estimate, there's far more weight behind their calculations and the shareprice reflects that.

Slow burner but everyone can see the massive upside here.

This is far from a binary bet, phase 1 results won't change: "Analysis of samples from the lung shows that treatment with IFN-beta boosted the lungs' antiviral defences"

In times of market turmoil, a lot of money is placed in precious metals & minerals but the world needs food, energy & medicines.

Happy to hold for results after reading this extract from 2nd October 2019 RNS:

"The data being presented are from Part 1 of the study, in which patients were treated with inhaled IFN-beta when they did not have a cold or flu infection. Analysis of samples from the lung shows that treatment with IFN-beta boosted the lungs' antiviral defences, increasing Synairgen's confidence in the likelihood of a positive outcome in Part 2"

The dataset with which endpoints are met is the value.

Even with lower than anticipated results, there will be a dataset chalice laid down for SNG-001, it could be fast tracked into other trials with any combination of other drugs too. The situation is fluid as the world is searching for treatments at such a rapid pace.

Neither the researcher or the participant know who receives the real treatment or the placebo. Worldwide Industry recognized standard results for the trial.

Transformational for SNG to get this data in the bag.

Looking forward to seeing them.

That's from a very good (for us) trial report in Hong Kong for Covid-19. / Interferon.

With successful trial results and fast tracked approach SNG-001 will become part of the primary response to Covid-19, kick starting immune systems (directly to the infected area) with people tested positive even without any symptoms.

Transformational indeed.